Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been assigned an average rating of “Moderate Buy” from the eighteen brokerages that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $110.5455.

Several equities research analysts have commented on GPCR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Wolfe Research started coverage on Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Canaccord Genuity Group initiated coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 target price for the company. Finally, HC Wainwright lowered their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th.

Structure Therapeutics Price Performance

Shares of GPCR opened at $48.48 on Monday. Structure Therapeutics has a 1-year low of $15.80 and a 1-year high of $94.90. The stock has a market cap of $3.45 billion, a price-to-earnings ratio of -55.72 and a beta of -1.50. The firm has a 50 day simple moving average of $44.34 and a 200-day simple moving average of $56.52.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. On average, equities analysts expect that Structure Therapeutics will post -1.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Capricorn Fund Managers Ltd purchased a new position in shares of Structure Therapeutics in the 4th quarter worth approximately $17,568,000. First Light Asset Management LLC increased its position in shares of Structure Therapeutics by 61.5% during the third quarter. First Light Asset Management LLC now owns 197,350 shares of the company’s stock valued at $5,526,000 after acquiring an additional 75,124 shares during the last quarter. Casdin Capital LLC increased its position in shares of Structure Therapeutics by 26.9% during the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after acquiring an additional 330,000 shares during the last quarter. HighVista Strategies LLC lifted its holdings in Structure Therapeutics by 172.7% during the third quarter. HighVista Strategies LLC now owns 236,236 shares of the company’s stock worth $6,615,000 after acquiring an additional 149,615 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Structure Therapeutics by 63.1% in the fourth quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock worth $89,317,000 after purchasing an additional 496,726 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.